INSIGHTS ON CLINICAL TRIAL DESIGN

• Start-Up Speed vs. Total Trial Success: Balancing RTSM Priorities

  Don't let a fast startup compromise years of clinical success. Learn how to balance initial build speed with the long-term flexibility needed to handle protocol amendments and complex integrations.

• What If Therapeutic Area Expertise Isn't The Competitive Advantage We Think It Is?

  Rethink vendor evaluation by looking beyond indication experience to discover how cross-trial adaptability, proactive risk management, and team judgment drive true clinical trial resilience.

• Why Tax Reporting Matters In Clinical Trial Participant Payments

  Clinical trial participant payments can trigger often overlooked tax reporting obligations. Learn why early visibility into payments matters and how better tracking helps avoid compliance surprises.

• 8 Critical Questions To Ask Your IRB

  This article outlines eight essential questions to ask a potential IRB partner to assess their ability to help you navigate complex regulatory requirements while avoiding delays.

• The Future Of Patient Participation In Clinical Research

  2/18/2025

  To address challenges such as limited patient awareness, mistrust, and logistical barriers, the industry must embrace technology-driven solutions and community-centered outreach.

• Next-Generation ADC Trials – Turning Complexity Into Execution

  7/20/2026

  As ADC science advances, operational strategy becomes critical. Learn how smarter protocol design, real-time monitoring and collaborative execution can accelerate next-generation ADC trials.

• The Impact Of High Inflation And The Great Resignation On Clinical Site Budgeting

  10/30/2024

  The twin pressures of inflation and attrition prolong negotiations between sponsors and clinical sites, stalling drug development. Sponsors need up-to-date, reliable benchmark data to negotiate fair market value budgets.

• CNS Trials Are Difficult — Do They Have To Be?

  3/9/2026

  Clinical trials for central nervous system therapies face significant obstacles to approval, including subjective endpoints and complex patient selection. Consider a strategic approach for success.

• Why Inclusive Clinical Trials Win On Science, Speed, And Spend

  9/17/2025

  Sponsors who proactively integrate diversity into their trial designs from the earliest phases are finding that it’s not only a matter of fairness but a strategic advantage.